Barbara De Moerloose1,2, Ardine Reedijk3, Geertruida H de Bock4, Tim Lammens1,2, Valerie de Haas3, Barbara Denys5, Laurence Dedeken6, Marry M van den Heuvel-Eibrink7,8, Maroeska Te Loo9, Anne Uyttebroeck10, An Van Damme11, Jutte Van der Werff-Ten Bosch12, Jozsef Zsiros13, Gertjan Kaspers3,7,14, Eveline de Bont3,15. 1. Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium. 2. Cancer Research Institute Ghent, Ghent, Belgium. 3. Dutch Childhood Oncology Group (DCOG), The Hague, the Netherlands. 4. Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 5. Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent, Belgium. 6. Department of Pediatric Hematology Oncology, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium. 7. Department of Pediatric Hematology-Oncology, Princess Máxima Center, Utrecht, the Netherlands. 8. Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands. 9. Department of Pediatric Hematology-Oncology, Radboud University Medical Center, Nijmegen, the Netherlands. 10. Department of Pediatrics, University Hospital Gasthuisberg, Leuven, Belgium. 11. Department of Pediatrics, University Hospital Saint-Luc, Brussels, Belgium. 12. Department of Pediatrics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium. 13. Department of Pediatric Oncology, Amsterdam Medical Center, Emma Children's Hospital, Amsterdam, the Netherlands. 14. Department of Pediatric Oncology, VU University Medical Center, Amsterdam, the Netherlands. 15. Department of Pediatric Hematology-Oncology, University Medical Center Groningen, Beatrix Children's Hospital, University of Groningen, Groningen, the Netherlands.
Abstract
BACKGROUND: Children with acute myeloid leukemia (AML) have a 70% survival rate with treatment regimens containing high doses of cytarabine and anthracyclines and, in some, hematopoietic stem cell transplantation (allo-HSCT). PROCEDURE: In this multicenter Dutch-Belgian protocol (DB AML-01), 112 children with de novo AML were included. Treatment was stratified according to day 15 bone marrow response after the first induction course. Poor responders received a second course without delay while good responders awaited hematological recovery. Patients achieving CR after two induction courses continued with three consolidation courses without HSCT in CR1. RESULTS: The overall remission rate was 93.5%. After a median follow-up of 4.1 years, three-year event-free survival (EFS) was 52.6% (95% CI, 42.9%-61.3%), three-year cumulative incidence of relapse 39.7% (95% CI, 30.1%-49.0%), and three-year overall survival (OS) 74.0% (95% CI, 64.8%-81.2%). Significantly more events occurred in patients with high WBC at diagnosis or FLT3-ITD/NPM1-WT, whereas core binding factor (CBF) leukemia had a significantly better EFS. KMT2A rearrangements and age > 10 years negatively impacted OS. CONCLUSIONS: DB AML-01 response-guided therapy results in a favorable OS, particularly for children with CBF leukemia, children younger than 10 years or with initial WBC counts below 100 × 109 /L. Outcome of patients with FLT3-ITD/NPM1-WT remains poor and warrants alternative treatment strategies.
BACKGROUND:Children with acute myeloid leukemia (AML) have a 70% survival rate with treatment regimens containing high doses of cytarabine and anthracyclines and, in some, hematopoietic stem cell transplantation (allo-HSCT). PROCEDURE: In this multicenter Dutch-Belgian protocol (DB AML-01), 112 children with de novo AML were included. Treatment was stratified according to day 15 bone marrow response after the first induction course. Poor responders received a second course without delay while good responders awaited hematological recovery. Patients achieving CR after two induction courses continued with three consolidation courses without HSCT in CR1. RESULTS: The overall remission rate was 93.5%. After a median follow-up of 4.1 years, three-year event-free survival (EFS) was 52.6% (95% CI, 42.9%-61.3%), three-year cumulative incidence of relapse 39.7% (95% CI, 30.1%-49.0%), and three-year overall survival (OS) 74.0% (95% CI, 64.8%-81.2%). Significantly more events occurred in patients with high WBC at diagnosis or FLT3-ITD/NPM1-WT, whereas core binding factor (CBF) leukemia had a significantly better EFS. KMT2A rearrangements and age > 10 years negatively impacted OS. CONCLUSIONS: DB AML-01 response-guided therapy results in a favorable OS, particularly for children with CBF leukemia, children younger than 10 years or with initial WBC counts below 100 × 109 /L. Outcome of patients with FLT3-ITD/NPM1-WT remains poor and warrants alternative treatment strategies.
Authors: Romy E Van Weelderen; Kim Klein; Bianca F Goemans; Wim J E Tissing; Tom F W Wolfs; Gertjan J L Kaspers Journal: Cancers (Basel) Date: 2022-06-28 Impact factor: 6.575
Authors: Barbara Depreter; Barbara De Moerloose; Karl Vandepoele; Anne Uyttebroeck; An Van Damme; Eva Terras; Barbara Denys; Laurence Dedeken; Marie-Françoise Dresse; Jutte Van der Werff Ten Bosch; Mattias Hofmans; Jan Philippé; Tim Lammens Journal: Pediatr Res Date: 2020-10-17 Impact factor: 3.756
Authors: Ditte J A Løhmann; Peter H Asdahl; Jonas Abrahamsson; Shau-Yin Ha; Ólafur G Jónsson; Gertjan J L Kaspers; Minna Koskenvuo; Birgitte Lausen; Barbara De Moerloose; Josefine Palle; Bernward Zeller; Lillian Sung; Henrik Hasle Journal: Cancer Med Date: 2019-09-18 Impact factor: 4.452
Authors: Barbara Depreter; Barbara De Moerloose; Karl Vandepoele; Anne Uyttebroeck; An Van Damme; Barbara Denys; Laurence Dedeken; Marie-Françoise Dresse; Jutte Van der Werff Ten Bosch; Mattias Hofmans; Tessa Kerre; Bart Vandekerckhove; Jan Philippé; Tim Lammens Journal: Hemasphere Date: 2020-02-26
Authors: Jae Min Lee; Eu Jeen Yang; Kyung Mi Park; Young-Ho Lee; Heewon Chueh; Jeong Ok Hah; Ji Kyoung Park; Jae Young Lim; Eun Sil Park; Sang Kyu Park; Heung Sik Kim; Ye Jee Shim; Jeong A Park; Eun Jin Choi; Kun Soo Lee; Ji Yoon Kim; Young Tak Lim Journal: Children (Basel) Date: 2021-02-05
Authors: A Birgitta Versluijs; Coco C H de Koning; Arjan C Lankester; Stefan Nierkens; Wouter J Kollen; Dorine Bresters; Caroline A Lindemans; Jaap Jan Boelens; Marc Bierings Journal: Blood Adv Date: 2022-03-22
Authors: Jolien Vanhooren; Laurens Van Camp; Barbara Depreter; Martijn de Jong; Anne Uyttebroeck; An Van Damme; Laurence Dedeken; Marie-Françoise Dresse; Jutte van der Werff Ten Bosch; Mattias Hofmans; Jan Philippé; Barbara De Moerloose; Tim Lammens Journal: Cancers (Basel) Date: 2022-04-22 Impact factor: 6.639
Authors: Barbara Depreter; Karin E Weening; Karl Vandepoele; Magnus Essand; Barbara De Moerloose; Maria Themeli; Jacqueline Cloos; Diana Hanekamp; Ine Moors; Inge D'hont; Barbara Denys; Anne Uyttebroeck; An Van Damme; Laurence Dedeken; Sylvia Snauwaert; Glenn Goetgeluk; Stijn De Munter; Tessa Kerre; Bart Vandekerckhove; Tim Lammens; Jan Philippé Journal: Haematologica Date: 2019-08-01 Impact factor: 9.941
Authors: Tara White; Gertjan Kaspers; Jonas Abrahamsson; Nira Arad-Cohen; Daniela Cianci; Jose Fernandez; Shau-Yin Ha; Henrik Hasle; Barbara De Moerloose; C Michel Zwaan; Bianca F Goemans Journal: Br J Haematol Date: 2022-02-04 Impact factor: 8.615